AHA Scientific Sessions 2025 Abstract

Tirzepatide Reduces the Risk of Major Adverse Cardiovascular Events: An Individual Participant Data Meta-analysis of Phase 3 Randomized Clinical Trials

By Arya Aminorroaya, Evangelos K. Oikonomou, Dhruva Biswas, Ania M. Jastreboff, Rohan Khera

Trial in peopleInterventions

The paper

Arya Aminorroaya, Evangelos K. Oikonomou, Dhruva Biswas, Ania M. Jastreboff, Rohan Khera

Yale University

AHA Scientific Sessions 2025 Abstract, 3 Nov 2025

Presented at AHA Scientific Sessions 2025, abstract 4361308

doi.org/10.1161/circ.152.suppl_3.4361308

Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine4 Oct 2026
Retatrutide reduces weight and pain in adults with obesity